SPRO stock icon

Spero Therapeutics
SPRO

$1.48
0.67%

Market Cap: 79.9M

 

About: Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Employees: 46

0
Funds holding %
of 6,702 funds
Analysts bullish %
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

4% more funds holding

Funds holding: 48 [Q4 2023] → 50 (+2) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0.57% less ownership

Funds ownership: 26.07% [Q4 2023] → 25.5% (-0.57%) [Q1 2024]

83% less capital invested

Capital invested by funds: $143M [Q4 2023] → $23.6M (-$119M) [Q1 2024]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$7
373%
upside
Avg. target
$7
373%
upside
High target
$7
373%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
373%upside
$7
Buy
Reiterated
16 May 2024
HC Wainwright & Co.
Raghuram Selvaraju
373%upside
$7
Buy
Reiterated
18 Mar 2024

Financial journalist opinion